Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TGTX Tg Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TGTX
Price (delayed)
$36.02
Market cap
$5.72B
P/E Ratio
133.41
Dividend/share
N/A
EPS
$0.27
Enterprise value
$5.84B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
The equity is up by 48% year-on-year and by 7% since the previous quarter
The revenue rose by 34% YoY and by 17% QoQ
Tg Therapeutics's EPS has surged by 69% QoQ but it has decreased by 7% YoY
The company's net income has surged by 67% QoQ but it fell by 5% YoY
TGTX's debt has soared by 129% YoY
The gross margin has decreased by 7% YoY
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
158.76M
Market cap
$5.72B
Enterprise value
$5.84B
Price to earnings (P/E)
133.41
Price to book (P/B)
23.84
Price to sales (P/S)
13.67
EV/EBIT
82.96
EV/EBITDA
82.9
EV/Sales
15.11
Revenue
$386.39M
Gross profit
$337.8M
Operating income
$59.82M
Net income
$39.15M
EBIT
$70.37M
EBITDA
$70.41M
Free cash flow
-$61.1M
Per share
Balance sheet
Liquidity
EPS
$0.27
EPS diluted
$0.24
Free cash flow per share
-$0.42
Book value per share
$1.51
Revenue per share
$2.63
TBVPS
$4.48
Total assets
$656.69M
Total liabilities
$419.4M
Debt
$252.59M
Equity
$237.29M
Working capital
$484.3M
Debt to equity
1.06
Current ratio
4.02
Quick ratio
2.92
Net debt/EBITDA
1.69
Margins
Efficiency
Dividend
EBITDA margin
18.2%
Gross margin
87.4%
Net margin
10.1%
Operating margin
15.5%
Return on assets
7%
Return on equity
18.9%
Return on invested capital
14%
Return on capital employed
14.2%
Return on sales
18.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
2.43%
1 week
0.03%
1 month
1.55%
1 year
112.13%
YTD
19.67%
QTD
-8.65%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$386.39M
Gross profit
$337.8M
Operating income
$59.82M
Net income
$39.15M
Gross margin
87.4%
Net margin
10.1%
The company's net income has surged by 67% QoQ but it fell by 5% YoY
The operating income has grown by 43% from the previous quarter and by 24% YoY
TGTX's net margin is up by 42% QoQ but it is down by 29% YoY
The revenue rose by 34% YoY and by 17% QoQ
Price vs fundamentals
How does TGTX's price correlate with its fundamentals
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
133.41
P/B
23.84
P/S
13.67
EV/EBIT
82.96
EV/EBITDA
82.9
EV/Sales
15.11
Tg Therapeutics's EPS has surged by 69% QoQ but it has decreased by 7% YoY
The equity is up by 48% year-on-year and by 7% since the previous quarter
The P/B is 17% above the last 4 quarters average of 20.4 and 7% above the 5-year quarterly average of 22.2
The P/S is 100% below the 5-year quarterly average of 4340.1 but 13% above the last 4 quarters average of 12.1
The revenue rose by 34% YoY and by 17% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
The company's return on equity has surged by 52% QoQ but it fell by 40% YoY
The ROA has contracted by 47% YoY but it has grown by 46% from the previous quarter
TGTX's ROIC is down by 36% YoY but it is up by 20% QoQ
Tg Therapeutics's return on sales has increased by 21% QoQ but it has decreased by 2.2% YoY
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 57% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 97% YoY and by 18% QoQ
The total assets has soared by 76% YoY and by 14% QoQ
TGTX's debt is 6% higher than its equity
TGTX's debt has soared by 129% YoY
The debt to equity has soared by 54% YoY but it has contracted by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.